Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash

Witherspoon, Joslyn N.; Wagner, Litiele Evelin; Rademaker, Alfred; West, D. P.; Rosenbaum, S. E.; Lacouture, Mario E.

doi:10.1200/jco.2008.26.15_suppl.9559

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…63 The rash may affect patients' QoL, with median Skindex-16 scores of 27, 49, and 62, corresponding to grade 1, grade 2, and grade 3 rash, respectively. 64 Affected patients are at increased risk for secondary infections at sites manifesting dermatologic toxicities, with 38% developing infections with bacterial (29%), viral (5%) and fungal (10.4%) microorganisms. 65 There is a lack of global consensus on management, while treatment guidelines are based mostly on anecdotal evidence and expert opinions.…”

Section: Dermatologic Adverse Events Arising From Novel Targeted Antimentioning

confidence: 99%

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Balagula

Rosen

Lacouture

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Dermatologic Adverse Events Arising From Novel Targeted Antimentioning

confidence: 99%

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Balagula

Rosen

Lacouture

2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…рекомендаций лечащим врачам необходимо обратиться к действующей инструкции для каждого ИТК-EGFR [39][40][41][42][43]45]. Лечение ИТК-EGFR может быть возобновлено только в случае регрессирования сыпи до ≤ 2 степени [39][40][41].…”

Section: лечение дерматологических няunclassified

“…В исследованиях III фазы у 25-95% пациентов наблю-дались НЯ любой степени и 1-14% -НЯ ≥3 степени (табл. 9) [11][12][13][14][15][16][17][18][19][20][39][40][41][42][43][44][45][46][47][48].…”

Section: желудочнокишечные нежелательные явления диареяunclassified

Algorithms for Management of Patients With Adverse Events on Therapy With Tyrosine Kinase Inhibitors Egfr

Сакаева¹

2017

Med. sov.

View full text Add to dashboard Cite

С емейство рецепторов ErbB является одной из наиболее широко изученных систем передачи сигналов [1]. Семейство ErbB включает четыре мембранно-связанных структурно родственных рецепто-ра тирозинкиназы: рецептор EGF (EGFR; также известен как ErbB1), HER2 (ErbB2), ErbB3 и ErbB4 [2]. Путь ErbB является одной из наиболее широко изученных систем передачи сигналов, вовлеченных в функционирование нормальных клеток, и при некоторых типах рака [1]. Нарушение регуляции активности рецепторов семейства ErbB и нисходящих сигнальных путей связано с развити-ем некоторых опухолей у человека.Механизм активации передачи сигналов ErbB зависит от лиганд-индуцированной стабильности гомо-или гете-родимеров, образованных различными тирозинкиназами рецепторов семейства ErbB [3]. Рецепторы семейства ErbB являются клинически доказанными мишенями для новых противоопухолевых препаратов [4][5][6][7].Ингибиторы EGFR показаны для лечения колорек-тального рака (панитумумаб, цетуксимаб), немелкокле-точного рака легкого (гефитиниб, эрлотиниб, афатиниб), плоскоклеточного рака головы и шеи (цетуксимаб), рака поджелудочной железы (эрлотиниб).В отличие от цитотоксической химиотерапии, лечение ингибиторами EGFR сопровождается минимальными неспеци фическими и гематологическими побочными эффектами.Активирующие мутации гена рецептора EGFR явля-ются наиболее значимыми предикторами ответа на ингибиторы тирозинкиназы EGFR (ИТК-EGFR) гефити- Ключевые слова: местнораспространенный и метастатический немелкоклеточный рак легкого, ингибиторы тирозин-киназы EGFR, терапия, нежелательные явления. D.D. SAKAEVA, MD, Prof., Republican Oncologic Dispensary of the Ministry of Health of the Republic of Bashkortostan, Ufa ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFRThe tyrosine kinase inhibitors (TKIs) of the epidermal receptor growth factor (EGFR) such as gefitinib, erlotinib and afatinib, are the standard first-line therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC) with frequent mutations of the EGFR gene. These drugs are more effective from the point of view of frequency response (FR) and survival without progression (SWP), less toxic and better tolerated than the standard two-component chemotherapy based on platinum drugs. The most frequent adverse events (AE) are gastrointestinal (GI) (diarrhea and stomatitis/mucositis) and dermatological (rash, dry skin and paronychia). They are usually mild, but in some cases symptoms can be moderate and more severity and have a negative impact on quality of life (QOL) of the patient and can require dose adjustment or discontinuation of treatment. Management of AEs, including preventive measures, supportive therapy, temporary cancellation and a reduction in the dose of the drug is important. Recommendations for the prevention and treatment of dermatological toxicity (rash, dry skin and paronychia) and toxicity for the gastrointestinal tract (diarrhoea, stomatitis and mucositis) related to therapy TKI-EGFR are developed. These guidelines descri...

show abstract

“…When a dermatology-specific QoL questionnaire was Review used to assess the effect of EGFR-inhibitor-associated rash (ranging in severity from grade 1 to 3 according to the NCI-CTCAE Version 3.0) on 58 patients' well-being, emotions were found to be significantly affected more than either symptoms or function (p < 0.0001) [26]. A greater severity of rash was significantly associated with a detrimental impact on symptom (p = 0.0006), emotional (p < 0.0001) and functional (p = 0.001) aspects of the QoL questionnaire, and resulted in a negative impact on overall score (p < 0.0001) [27].…”

Section: Impact Of Dermatologic Aesmentioning

confidence: 99%

“…Dermatologic reactions also affect a patient's quality of life (QoL) [26]. When a dermatology-specific QoL questionnaire was Review used to assess the effect of EGFR-inhibitor-associated rash (ranging in severity from grade 1 to 3 according to the NCI-CTCAE Version 3.0) on 58 patients' well-being, emotions were found to be significantly affected more than either symptoms or function (p < 0.0001) [26].…”

Section: Impact Of Dermatologic Aesmentioning

confidence: 99%

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

Lacouture¹,

Schadendorf

Chu

et al. 2013

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash

Cited by 10 publications

References 0 publications

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

Algorithms for Management of Patients With Adverse Events on Therapy With Tyrosine Kinase Inhibitors Egfr

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

Contact Info

Product

Resources

About